SCHEMBL25331964

SCHEMBL25331964

CC(=O)c1nc(C2CC2)ccc1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.45
KDM4E B2RXH2 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 3/20 0.37
MAPT P10636 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
PDE10A Q9Y233 4/20 0.36
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35
GABRB2 P47870 1/20 0.35
GABRA4 P48169 1/20 0.35
GABRE P78334 1/20 0.35
GABRA6 Q16445 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15057161 0.88 POLB (0.49) POLBKDM4EKMT2AALDH1A1MAPT
SCHEMBL25949015 0.87 POLB (0.37) POLBKDM4EKMT2APDE10AMEN1
SCHEMBL25332852 0.83 POLB (0.42) POLBKDM4EKMT2AALDH1A1MAPT
SCHEMBL25333467 0.83 POLB (0.42) POLBKDM4EKMT2AALDH1A1MAPT
SCHEMBL15058026 0.83 POLB (0.42) POLBKDM4EKMT2AALDH1A1MAPT
SCHEMBL21816284 0.79 GABRP (0.53) POLBKDM4EKMT2AALDH1A1MAPT
SCHEMBL18412836 0.78 TRPV3 (0.39) PDE10A
SCHEMBL24680127 0.76 POLB (0.41) POLBKDM4EKMT2AALDH1A1MAPT
SCHEMBL27704314 0.76 POLB (0.47) POLBKDM4EKMT2AALDH1A1MAPT
SCHEMBL13544719 0.76 POLB (0.47) POLBKDM4EKMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066369-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES NodThera Limited (GB) 2025-02-27 US disclosed
EP-4460505-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES Nodthera Limited (GB) 2024-11-13 EP disclosed
CN-118922421-A Bicyclic phthalazin-1 (2H) -one derivatives and related uses 诺瑟拉有限公司 2024-11-08 CN disclosed
WO-2023133271-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES NodThera Limited (GB) 2023-07-13 WO disclosed
WO-2023133271-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES NodThera Limited (GB) 2023-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066369-A1 BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES IL1B, NLRP3, IL1A POLB 3079/4885KDM4E 4064/4885KMT2A 3863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.